Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2010 by The Cleveland Clinic.
Recruitment status was  Active, not recruiting
Information provided by:
The Cleveland Clinic Identifier:
First received: January 10, 2008
Last updated: June 1, 2010
Last verified: June 2010
The purpose of this study is to establish a genebank repository of blood samples and data to generate information about the hereditary (genetic) basis of atrial fibrillation.

Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

Resource links provided by NLM:

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • Atrial fibrillation [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Stroke [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
plasma, serum, buffy coat, DNA

Estimated Enrollment: 1300
Study Start Date: August 2005
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
atrial fibrillation
Atrial fibrillation
Control subjects with no atrial fibrillation

Detailed Description:
Blood samples and data will be collected from subjects with atrial fibrillation and normal controls. The primary aim of future research using these samples is to identify mechanisms and pathogenesis of atrial fibrillation. Through this information, we hope to identify targets for new therapies and improve knowledge and understanding of atrial fibrillation. Identification of disease genes could improve strategies that prevent progression of atrial fibrillation to more persistent disease.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects with atrial fibrillation

Inclusion Criteria for Atrial Fibrillation group:

  • Male or female at least 18 years old
  • Subjects with a history of or current Atrial Fibrillation
  • Subjects able to give informed consent

Inclusion Criteria for Controls:

  • Male or female at least 18 years old
  • Subjects with no history of Atrial Fibrillation
  • Subjects able to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00599118

United States, Ohio
Cleveland Clinical Foundation
Cleveland, Ohio, United States, 44145
Sponsors and Collaborators
The Cleveland Clinic
Principal Investigator: Mina K Chung, MD The Cleveland Clinic
  More Information

Responsible Party: Mina K. Chung, MD, Cleveland Clinic Foundation Identifier: NCT00599118     History of Changes
Other Study ID Numbers: 8271 
Study First Received: January 10, 2008
Last Updated: June 1, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by The Cleveland Clinic:
Atrial Fibrillation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on October 25, 2016